Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week High - Here's What Happened

Key Points

• Takeda Pharmaceutical shares reached a new 52-week high at $15.69, closing at $15.59 with a trading volume of 561,228 shares.
• Zacks Research downgraded the stock's rating from "hold" to "strong sell," while MarketBeat indicates a consensus rating of "Hold" among analysts.
• The company reported $0.52 EPS for the latest quarter, surpassing estimates of $0.47 but falling short of revenue expectations, posting $7.45 billion against estimates of $7.96 billion.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report)'s share price reached a new 52-week high during trading on Monday . The stock traded as high as $15.69 and last traded at $15.59, with a volume of 561228 shares trading hands. The stock had previously closed at $15.40.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Takeda Pharmaceutical has a consensus rating of "Hold".

Takeda Pharmaceutical Trading Down 1.5%

The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $48.08 billion, a P/E ratio of 50.37 and a beta of 0.22. The firm has a 50 day moving average of $14.81 and a 200-day moving average of $14.83.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities research analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors and hedge funds have recently added to or reduced their stakes in TAK. Cetera Investment Advisers lifted its stake in Takeda Pharmaceutical by 14.7% during the fourth quarter. Cetera Investment Advisers now owns 59,273 shares of the company's stock worth $785,000 after purchasing an additional 7,574 shares during the last quarter. Focus Partners Wealth lifted its stake in Takeda Pharmaceutical by 431.7% during the fourth quarter. Focus Partners Wealth now owns 79,499 shares of the company's stock worth $1,054,000 after purchasing an additional 64,548 shares during the last quarter. Laird Norton Wetherby Wealth Management LLC lifted its stake in Takeda Pharmaceutical by 15.2% during the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 39,220 shares of the company's stock worth $519,000 after purchasing an additional 5,167 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Takeda Pharmaceutical by 33.2% during the fourth quarter. Quantinno Capital Management LP now owns 481,833 shares of the company's stock worth $6,379,000 after purchasing an additional 120,120 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in Takeda Pharmaceutical during the fourth quarter worth $94,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.